EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study

Fernando Magro iD, Maria Manuela Estevinho iD, Gaia Catalano, Marta Patita, Bruno Arroja, Paula Lago, Isadora Rosa iD, Helena Tavares de Sousa iD, Paula Ministro, Irina Mocanu, Ana Vieira, Joana Castela und 14 weitere

United European Gastroenterology Journal · 2023

DOI: 10.1002/ueg2.12420 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift United European Gastroenterology Journal, 2023. Verfasst von Fernando Magro und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Crohn Disease. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Timely stratification of Crohn's disease (CD) is essential for patients' management. The use of noninvasive accurate biomarkers is key to monitor treatment and to pursue mucosal healing, the ultimate treatment endpoint in CD.

Objective

We aimed to evaluate the performance of readily available biomarkers and develop risk matrices to predict CD progression.

Methods

Data from 289 CD patients receiving infliximab (IFX) maintenance therapy for 2 years was collected; those patients were included in DIRECT, a prospective multicenter observational study. Disease progression was evaluated using two composite outcomes incorporating clinical and drug‐related factors, the first including IFX dose and/or frequency adjustments. Univariate and multivariable logistic regressions were used to calculate the odds ratios (OR) and to develop risk matrices.

Results

The isolated presence of anemia at least once during follow‐up was a significant predictor of disease progression (OR 2.436 and 3.396 [ p ≤ 0.001] for composite outcomes 1 and 2, respectively) regardless of confounding factors. Isolated highly elevated C‐reactive protein (CRP; >10.0 mg/L) and fecal calprotectin (FC; >500.0 μg/g) in at least one visit were also significant predictors, while milder elevations (3.1–10.0 mg/L and 250.1–500.0 μg/g) were only relevant when detected in at least two visits (consecutive or not). The combination of biomarkers in risk matrices had good ability to predict progression; patients simultaneously presenting anemia, highly elevated CRP and FC at least once had 42%–63% probability of achieving the composite outcomes.

Conclusion

The combined evaluation of hemoglobin, CRP, and FC in at least one time point and their incorporation into risk matrices seems to be the optimal strategy for CD management, as data from additional visits did not meaningfully influence the predictions and may delay decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseHumansInfliximabProspective StudiesBiomarkersPrognosisDisease Progression

Stichwörter der Autor:innen

Crohn's diseasebiomarkerscalprotectininfliximab

Substanzen

InfliximabBiomarkers

Autor:innen und Institutionen

  • Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Department of Gastroenterology, São João Hospital University Centre, Porto, Portugal.
  • Center for Health Technology and Services Research (CINTESIS), Porto, Portugal.
  • Unidade de Farmacologia Clínica, São João Hospital University Centre, Porto, Portugal.
  • Department of Gastroenterology, Vila Nova de Gaia Espinho Hospital Center, Vila Nova de Gaia, Portugal.
  • Department of Gastroenterology, Garcia da Orta Hospital, Almada, Portugal.

ORCID-Profile: Fernando Magro, Maria Manuela Estevinho, Isadora Rosa, Helena Tavares de Sousa, Joana Roseira, Laurent Peyrin-Biroulet

Zitieren

APA

Magro, F., Estevinho, M. M., Catalano, G., Patita, M., Arroja, B., Lago, P., Rosa, I., Tavares de Sousa, H., Ministro, P., Mocanu, I., Vieira, A., Castela, J., Moleiro, J., Roseira, J., Cancela, E., Sousa, P., Portela, F., Correia, L., Moreira, P., …, & GEDII (Grupo de Estudos da Doença Inflamatória Intestinal) (2023). How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12420

Vancouver

Magro F, Estevinho MM, Catalano G, Patita M, Arroja B, Lago P, et al. How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study. United European Gastroenterology Journal. 2023. doi:10.1002/ueg2.12420

BibTeX
@article{Magro2023,
  author = {Magro, Fernando and Estevinho, Maria Manuela and Catalano, Gaia and Patita, Marta and Arroja, Bruno and Lago, Paula and Rosa, Isadora and Tavares de Sousa, Helena and Ministro, Paula and Mocanu, Irina and Vieira, Ana and Castela, Joana and Moleiro, Joana and Roseira, Joana and Cancela, Eugénia and Sousa, Paula and Portela, Francisco and Correia, Luís and Moreira, Paula and Santiago, Mafalda and Dias, Sandra and Afonso, Joana and Danese, Silvio and Peyrin-Biroulet, Laurent and Dias, Cláudia Camila and GEDII (Grupo de Estudos da Doença Inflamatória Intestinal), GEDII (Grupo de Estudos da Doença Inflamatória Intestinal)},
  title = {How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study},
  journal = {United European Gastroenterology Journal},
  year = {2023},
  doi = {10.1002/ueg2.12420}
}
Kostenlos starten →